Zacks Investment Research Upgrades Neos Therapeutics, Inc. (NEOS) to “Hold”

Neos Therapeutics, Inc. (NASDAQ:NEOS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Several other research analysts have also recently weighed in on NEOS. Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research report on Tuesday, September 26th. Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Finally, Wells Fargo & Company set a $14.00 price objective on shares of Neos Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.00.

Shares of Neos Therapeutics (NASDAQ NEOS) opened at 10.25 on Tuesday. The stock has a 50 day moving average of $8.70 and a 200-day moving average of $8.70. The firm’s market capitalization is $287.82 million. Neos Therapeutics has a 1-year low of $4.85 and a 1-year high of $10.90.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.83). The company had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 611.78%. On average, equities analysts expect that Neos Therapeutics will post ($3.11) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Neos Therapeutics, Inc. (NEOS) to “Hold”” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/31/zacks-investment-research-upgrades-neos-therapeutics-inc-neos-to-hold.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its position in Neos Therapeutics by 167.9% during the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock valued at $1,971,000 after acquiring an additional 169,237 shares during the last quarter. DAFNA Capital Management LLC grew its position in Neos Therapeutics by 120.3% during the second quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock valued at $1,532,000 after acquiring an additional 114,600 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Neos Therapeutics during the second quarter valued at approximately $384,000. Stonepine Capital Management LLC bought a new position in Neos Therapeutics during the second quarter valued at approximately $4,125,000. Finally, Wells Fargo & Company MN grew its position in Neos Therapeutics by 130.3% during the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after acquiring an additional 27,174 shares during the last quarter. Institutional investors and hedge funds own 44.32% of the company’s stock.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

What are top analysts saying about Neos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neos Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit